ReviewPsychedelic medicine (New Rochelle, N.Y.)2023
Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.
Review in Psychedelic medicine (New Rochelle, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use.Scientific reports · 2026Article
- Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study.Journal of psychoactive drugs · 2025Article
- Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people.International journal of transgender health · 2025Article
- Psilocybin-assisted therapy and HIV-related shame.Scientific reports · 2024Article
- The library is open: a scoping review on queer representation in psychedelic research.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent trials of psychedelic-assisted therapy have suggested potential efficacy for the treatment of many health conditions that disproportionately impact sexual and gender minority (SGM) people, including major depressive disorder and alcohol and tobacco use disorders. Despite these promising findings, the potential benefits of psychedelics for SGM people have been largely ignored. First, we highlight SGM health inequities and discuss therapeutic applications of psychedelics based on current research. Next, grounded by the minority stress model and the psychological mediation framework, we describe the role of shame as a significant mediator between stigma-related stressors and negative health outcomes for SGM people. We then apply self-entropic broadening theory to examine the potential therapeutic applications of psychedelics to reduce chronic shame among SGM people, potentially mitigating health inequities, by (1) alleviating self-focused attention, (2) prompting positive behavioral changes, and (3) encouraging adaptive perspectives on faith and spirituality. Finally, we consider the limitations of psychedelic-assisted therapy and recommend tangible next steps for future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.